Passage timing calculation device, passage timing calculation method, and recording medium for recording program
US-2024352397-A1 · Oct 24, 2024 · US
Use of RNA for reprogramming somatic cells
US12378531B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12378531-B2 |
| Application number | US-202117241651-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2021 |
| Priority date | Dec 14, 2007 |
| Publication date | Aug 5, 2025 |
| Grant date | Aug 5, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, include the steps of introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
First claim
Opening claim text (preview).
The invention claimed is: 1. A cell population which comprises (i) RNA-transfected somatic cells subjected to electroporation, the RNA-transfected somatic cells containing in vitro transcribed mRNA encoding OCT4, SOX2, KLF4 and c-MYC, wherein the mRNA comprises a 5′-Cap structure and wherein the RNA-transfected cells express alkaline phosphatase and endogenous OCT4, and (ii) somatic cells not subjected to electroporation. 2. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are human cells transfected with RNA. 3. The cell population in accordance with claim 2 , wherein the human cells are adult human dermal fibroblasts transfected with RNA. 4. The cell population in accordance with claim 1 , wherein the somatic cells subjected to electroporation are fibroblasts. 5. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells express endogenous OCT4 for at least 7 days. 6. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are fibroblasts deposited at American Type Culture Collection under Catalog No. CCL-186 and subsequently transfected with RNA. 7. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are fibroblasts deposited at American Type Culture Collection under Catalog No. CRL-2097 and subsequently transfected with RNA. 8. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are derived by RNA-transfection of fibroblasts deposited at American Type Culture Collection under Catalog No. CCL-186. 9. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are derived by RNA-transfection of fibroblasts deposited at American Type Culture Collection under Catalog No. CRL-2097.
Assignees
Inventors
Classifications
Sox-2 · CPC title
Klf-4 · CPC title
Oct-3/4 · CPC title
c-Myc · CPC title
Genetically modified cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12378531B2 cover?
- Methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, include the steps of introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
- Who is the assignee on this patent?
- BioNTech SE, Tron—Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmb
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0696. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).